Technical Analysis for RVX - Resverlogix Corp.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.055 | 0.00% | 0.000 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% |
Alert | Time |
---|---|
Reversed from Up | about 17 hours ago |
20 DMA Resistance | about 17 hours ago |
10 DMA Resistance | about 17 hours ago |
Rose Above 20 DMA | about 18 hours ago |
Rose Above 10 DMA | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2018-12-18
Resverlogix Corp. Description
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Beta Clinic Biotechnology Disease RTT Medical Specialties Diseases Clinical Trial IPO Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.26 |
52 Week Low | 0.055 |
Average Volume | 38,363 |
200-Day Moving Average | 0.079 |
50-Day Moving Average | 0.064 |
20-Day Moving Average | 0.059 |
10-Day Moving Average | 0.058 |
Average True Range | 0.004 |
RSI (14) | 41.86 |
ADX | 16.9 |
+DI | 12.909 |
-DI | 24.470 |
Chandelier Exit (Long, 3 ATRs) | 0.054 |
Chandelier Exit (Short, 3 ATRs) | 0.066 |
Upper Bollinger Bands | 0.065 |
Lower Bollinger Band | 0.054 |
Percent B (%b) | 0.12 |
BandWidth | 19.224 |
MACD Line | -0.002 |
MACD Signal Line | -0.002 |
MACD Histogram | -0.0003 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.063 | ||||
Resistance 3 (R3) | 0.063 | 0.062 | 0.061 | ||
Resistance 2 (R2) | 0.062 | 0.060 | 0.061 | 0.061 | |
Resistance 1 (R1) | 0.058 | 0.059 | 0.058 | 0.058 | 0.060 |
Pivot Point | 0.057 | 0.057 | 0.056 | 0.056 | 0.057 |
Support 1 (S1) | 0.053 | 0.055 | 0.053 | 0.053 | 0.050 |
Support 2 (S2) | 0.052 | 0.054 | 0.051 | 0.049 | |
Support 3 (S3) | 0.048 | 0.052 | 0.049 | ||
Support 4 (S4) | 0.048 |